NASDAQ:CALC CalciMedica Q1 2025 Earnings Report $0.82 -0.11 (-12.06%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$0.83 +0.01 (+1.74%) As of 07:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CalciMedica EPS ResultsActual EPS-$0.36Consensus EPS -$0.43Beat/MissBeat by +$0.07One Year Ago EPSN/ACalciMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACalciMedica Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCalciMedica's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CalciMedica Earnings HeadlinesCalciMedica, Inc.: CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety DataJune 25, 2026 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC)June 25, 2026 | theglobeandmail.comGates. Google. The Pentagon.Bill Gates wrote a $100 million check. Google signed a 15-year contract. The Pentagon named it their top energy priority. All three are backing the same company - and the same energy source that holds 140 times global electricity demand. Last year a drilling crew cracked through three miles of solid rock in 16 days - the government had projected 64. On August 18th, Washington is handing this technology a tax credit advantage that solar and wind no longer receive.July 14 at 1:00 AM | Behind the Markets (Ad)CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension ProgramJune 24, 2026 | prnewswire.comCalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety DataJune 24, 2026 | prnewswire.comCalciMedica Inc Ordinary Shares CALCMay 19, 2026 | morningstar.comMSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC), Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses. The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients. CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
